A Diverse, Market-Driven Pipeline
The DDI works with world-renowned investigators who perform cutting-edge research in multidisciplinary teams.
Highlights of a few current projects in our pipeline:
Activated B Cells as a Therapeutic Cancer Platform
Investigators: Thomas L. Cherpes, MD, DVM; Rodolfo Vicetti Miguel, MD; and Nirk Quispe Calla, MD
A novel B cell-based cancer vaccine, with the potential to be personalized to an individual’s own tumor signature, is being developed for use in the treatment of a wide variety of cancer types.
DLL1 T Cell Immune Therapy to Fight Cancer (First-in-Class)
This team of researchers has developed a new class of molecules that modulate a signaling pathway in immune cells to reprogram the immune system to recognize and fight evasive cancer tumor cells.
Selective RAL A GTPase Inhibitors as a Cancer Treatment
The Ral A protein has been shown to be a critical node in the signaling pathways allowing growth of several types of cancer. This team is developing first-in-class, selective inhibitors of Ral A.
Estrogen Receptor Beta (ER-β) Agonist as a New Approach to Targeting a Cancer Driver
Investigator: Werner Tjarks, Dr.rer.nat.
A novel series of selective estrogen receptor beta agonists is in development for the treatment of cancer as well as the precancerous condition, nonalcoholic steatohepatitis (NASH).
Split Delivery and Functional Reconstitution of Immunotoxins via Dual Tumor-Targeted Pathways
Investigators: Dmitri Kudryashov, MD, PhD
The team is developing a unique strategy for increasing the safety profile of highly potent immunotoxins by ensuring that active toxins are produced only within cancer cells.
Mps1 Inhibitor as a Treatment for Solid Tumors
Investigators: Harold Fisk, PhD, in collaboration with Robert Brueggemeier, PhD; Tom Li, PhD; and Michael Darby, PhD
Mps1 is a protein that regulates cell division, and its overexpression is associated with poor outcomes in triple-negative breast cancer and other solid tumors. This team is developing selective inhibitors of Mps1.
PP2A Activator for Treatment of AML and Other Hematologic Malignancies
Protein phosphatase 2A (PP2A) is an important tumor suppressor that is frequently inactivated in acute myeloid leukemia (AML) and other hematologic malignancies. This team has developed a selective activator of PP2A to address the significant unmet need in AML.
AHR Hydrocarbon Receptor as a Target for Myeloma
Investigator: Don Benson, MD, PhD
The aryl hydrocarbon receptor (AHR) has been implicated as a sensor of environmental chemicals as well as a critical regulator of B-cell development. This team is evaluating small molecule inhibitors of AHR to address the significant unmet need in myeloma.
Building and Managing the DDI Pipeline
The DDI Pipeline is Focused on the Development of Therapeutics and Diagnostics for the Treatment of Cancer
- November 2011: Creation of Ohio State’s Drug Development Institute
- March 2013: First investments in DDI pipeline projects
- Building and managing the pipeline is a dynamic process:
- New projects are evaluated for probability of scientific and commercial success
- Projects are continually assessed, with the reallocation of investments to the most promising drug development projects
- Pipeline decisions are made early and rapidly:
- Data-driven go/no-go decisions
- Progress against planned development timelines
- Changes to the commercial or intellectual property landscape
- Accelerates projects forward using measurable milestones and industry-standard go/no-go decision criteria
For more information, contact the DDI at email@example.com.